A&G Pharmaceutical, Inc. Alternatives & Competitors

12 companies similar to A&G Pharmaceutical, Inc. — Pioneering the future of cancer treatment and diagnostics through innovative mon...

FibroGen, Inc.

Committed to being a place where our people and science thrive.

347 Post-IPO Equity $308.02M

San Francisco, United Sta...

Biopharma Biotechnology +2

Adrenomed AG

An innovative biomarker-guided precision medicine solution for patients in acute care with...

16 Series E $47.70M

Hennigsdorf, Germany

Biotechnology Pharmaceutical

Apollomics

We are a biopharmaceutical company committed to the discovery and development of mono- and...

26 Post-IPO Equity $262.60M

Foster City, United State...

Biotechnology Health Care +1

Farcast Biosciences

24,000 human tumors and counting - building the most precise functional precision tumor mi...

38 Pre-Seed $74.63M

Bengaluru, India

Biotechnology Health Care +1

Track all A&G Pharmaceutical, Inc. competitors

Get real-time alerts when any of these companies raise funding, hire, or show growth signals.

See how it works

Agensys

Pioneering advanced treatments for cancer with innovative therapeutic antibodies and drug...

Series D $106.40M

Biotechnology Health Care +1

GamaMabs Pharma

Advancing the future of immuno-oncology with innovative monoclonal antibody treatments

7 Series B $18.10M

Biotechnology Health Care +1

ImmunoBiochem Corporation

Improving patient outcomes through innovations in biological therapeutics

4 Seed

Toronto, Canada

Biotechnology Health Care +1

Antharis Therapeutics, Inc.

Antharis Therapeutics is a multinational biopharmaceutical company developing new, cutting...

San Diego, United States

Biopharma Biotechnology +1

EpimAb Biotherapeutics, Inc.

Advancing a Best-in-class Bispecific Antibody Format

40 Series C $219.00M

Shanghai, China

Biopharma Biotechnology +2

FogPharma

Until everything is druggable.

146 Series E $530.27M

Cambridge, United States

Biopharma Biotechnology +3

Kernal Biologics

KernalBio creates mRNA therapies that instruct specific cells on how to make their own med...

22 Series A $26.82M

Cambridge, United States

Biotechnology Health and Wellness +1

Metaclipse Therapeutics Corporation

Delivering breakthrough technologies to treat cancer and infectious disease

6 Grant $2.55M

Atlanta, United States

Biotechnology Health and Wellness

About A&G Pharmaceutical, Inc.

A&G Pharmaceutical is a pioneering theranostics company that focuses on developing monoclonal antibodies targeting cancer-specific markers for both therapeutic and diagnostic purposes. The company's innovative approach to utilizing its patented growth factor, GP88, has led to the advancement of diagnostic test kits spe...

Business keywords

Monoclonal Antibodies, Cancer Treatment, Diagnostics, Theranostics, Drug Development, Cancer-specific Markers, Breast Cancer, GP88 Growth Factor, Equity Capital, Scientific Research, Biopharmaceuticals

Frequently Asked Questions

Companies similar to A&G Pharmaceutical, Inc. include FibroGen, Inc., Adrenomed AG, Apollomics, Farcast Biosciences, Agensys. They work in Biotechnology and Health and Wellness and share A&G Pharmaceutical, Inc.'s focus on monoclonal antibodies, drug development and cancer treatment.

Bounce Watch lists 12 companies that share A&G Pharmaceutical, Inc.'s industries and are closest to it in business tags, services, target customers, business model and size.

Don't just read about them. Follow them.

BounceWatch watches A&G Pharmaceutical, Inc. and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.

See how it works

Explore Related

A&G Pharmaceutical, Inc. Profile FibroGen, Inc. Alternatives Adrenomed AG Alternatives Apollomics Alternatives All Companies All Signals Trend Reports

Compiled from the BounceWatch company index. We last looked at A&G Pharmaceutical, Inc. on 12 Sep 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 28 May 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.